drugset
drugset / Trial / NCT04195919

The Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of Evogliptin in Hemodialysis Patients

NCT04195919 ↗

Phase 1 Completed 17 enrolled Dong-A ST Co., Ltd.
Non-randomizedParallel-groupOpen-labelHealth-services research

Summary

A clinical study to investigate the pharmacokinetics/ pharmacodynamics and safety/tolerability of Evogliptin in hemodialysis patients

Timeline

Start
2020-07-10
Primary completion
2021-05-24
Completion
2021-05-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Evogliptin Small molecule 5 mg Oral

Indications

No indication recorded.